

# Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target

The results of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial have been recently reported (1–2). Nateglinide, a member of the meglitinide class, which has been shown to lower postprandial hyperglycemia by increasing the first phase of insulin secretion, was not effective in decreasing both the new cases of diabetes and the new cardiovascular events in a population at high risk (1). Valsartan, an angiotensin (AT-1) blocker, was ineffective on cardiovascular events but significantly—even marginally—reduced the onset of new diabetes (2). The negative results of nateglinide immediately raised the concern about the possibility that postprandial hyperglycemia could be considered an independent risk factor for cardiovascular disease (CVD) and whether its treatment may give any advantage in the management of diabetes (3).

Diabetologists have long debated whether the lack of insulin action (insulin resistance) or impaired insulin secretion represents the primary pathological mechanism underlying type 2 diabetes. Recent analyses confirm that impaired pancreatic  $\beta$ -cell glucose sensitivity and whole-body insulin sensitivity are strong predictors of a progression to hyperglycemia (4). Conversely, numerous studies have shown that acute insulin secretion defects represent a powerful early predictor of diabetes progression.

During the progression from normal glucose tolerance to increasingly severe type 2 diabetes, first-phase insulin secretion (FPIS) is an early casualty. Prior to the diagnosis of diabetes, insulin response to mealtime glucose becomes delayed and blunted; eventually, it is lost (5). In a landmark study, Polonsky et al. (5) showed that FPIS responses were more sluggish and less dramatic in diabetic individuals. In another analysis, a marked and increasing loss of the early-phase  $\beta$ -cell secretory response to a meal challenge correlated with increasing postprandial hyperglycemia in a group of individuals recently diagnosed with diabetes (6). Together these data indicate that declining FPIS and postprandial hy-

perglycemia are key features of type 2 diabetes.

The relative contribution of fasting versus postprandial glucose (PPG) to overall glycemic exposure was a matter of considerable controversy until recently when influential analyses from Monnier et al. (7,8) appeared showing that the contribution of postprandial hyperglycemia varies depending on an individual's degree of glycemic control. This fundamental insight—that postprandial glycemia excursions make an ever greater contribution to A1C as glycemic control improves—has been confirmed in other settings (9) and has been extended to subjects whose A1C values lie well within the normal range (10). Based on this information, one would predict that attempts to treat patients to target, especially when aiming for ambitious A1C targets, will generally fail unless PPG is controlled. Many studies directly support this hypothesis (11), including the recent data of the Treating to Target in Type 2 diabetes (4-T) trial (12) and in particular the data after 1 year (13), where even the conclusions of the authors were, surprisingly, different.

The link between postprandial hyperglycemia and the risk for CVD has been recently highlighted due to the identified linear relationship, widely confirmed in many studies, between the risk of CVD death and the glucose value at 2 h during an oral glucose tolerance test (OGTT) (11). A recent study (14) consistently confirmed postprandial hyperglycemia as an independent risk factor for CVD in type 2 diabetes. However, most of the epidemiological data supporting this concept were available from studies using the OGTT (11). This approach raised the concern that because the OGTT could not be considered a meal, the existing relationship between the 2-h glucose values during an OGTT did not necessarily mean that these subjects could have increased postprandial hyperglycemia after a meal. This concern has now been clarified. A strong relationship between the level of glycemia after an OGTT and after a meal has been demonstrated (15), particularly

in terms of peak values, thereby suggesting that this issue is now over.

However, even epidemiological data support the concept that postprandial hyperglycemia is a risk factor for CVDs, the main concern regards the need for evidence that lowering postprandial hyperglycemia CVD can be prevented. The Study To Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial has shown, as a predefined secondary end point, that treating postprandial hyperglycemia may reduce the incidence of new cardiovascular events in people with impaired glucose tolerance (16), a finding confirmed in type 2 diabetes by a meta-analysis on the use of acarbose (17). However, the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study (18) last year and the NAVIGATOR (1) study now, have failed to confirm this finding.

What has the NAVIGATOR study demonstrated? In my opinion, it has only demonstrated that nateglinide does not reduce cardiovascular events. That is all. Unfortunately, NAVIGATOR is another study, as is the HEART2D study (18), that does not help to answer whether lowering postprandial hyperglycemia reduces the incidence of CVD.

The HEART2D study failed to reach the predetermined difference in postprandial hyperglycemia of 2.5 mmol/l, the mean difference at the end of the study being only 0.8 mmol/l, less than one-third of the goal, even if significantly different between the two groups (18). In the NAVIGATOR trial, nateglinide not only did not improve postprandial hyperglycemia, but the glucose levels 2 h after a glucose challenge in the annual OGTTs were higher in the nateglinide group than in the placebo group (1). Furthermore, the incidence of new diabetes was also higher in the treated group than in the placebo group (1).

As already suggested (19), we have to pay attention to the level of risk in the patients included in the studies. We have learned that the control of hyperglycemia may have a different impact in the pri-



- terms of insulin secretion in non-insulin-dependent diabetes mellitus. *N Engl J Med* 1988;318:1231–1239
6. Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. *Diabetes Res Clin Pract* 1994; 26:177–187
  7. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). *Diabetes Care* 2003;26:881–885
  8. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycaemic control precedes stepwise deterioration of fasting with worsening diabetes. *Diabetes Care* 2007;30:263–269
  9. Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P, Meigs JB. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. *Diabetologia* 2006;49:846–854
  10. Woerle HJ, Pimenta WP, Meyer C, Gosmanov NR, Szoke E, Szombathy T, Mitrakou A, Gerich JE. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1C values. *Arch Intern Med* 2004;164:1627–1632
  11. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J. Postprandial glucose regulation and diabetic complications. *Arch Intern Med* 2004;164:2090–2095
  12. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK, 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. *N Engl J Med* 2009;361:1736–1747
  13. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC, 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. *N Engl J Med* 2007;357:1716–1730
  14. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. *J Clin Endocrinol Metab* 2006;91:813–819
  15. Meier JJ, Baller B, Menge BA, Gallwitz B, Schmidt WE, Nauck MA. Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa? *Diabetes Obes Metab* 2009;11: 213–222
  16. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA* 2003;290:486–494
  17. Hanefeld M, Catagay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. *Eur Heart J* 2004;25:10–16
  18. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. *Diabetes Care* 2009;32:381–386
  19. Ceriello A. Postprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer? *Diabetes Care* 2009;32:521–522
  20. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358: 2545–2559
  21. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560–2572
  22. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360:129–139
  23. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–1589
  24. Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. *Diabetologia* 2009;52:1990–2000
  25. Mita T, Watada H, Shimizu T, Tamura Y, Sato F, Watanabe T, Choi JB, Hirose T, Tanaka Y, Kawamori R. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycaemic control. *Arterioscler Thromb Vasc Biol* 2007;27:2456–2462
  26. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* 2000;404:787–790
  27. Ceriello A, Ihnat M. "Glycaemic variability:" a new therapeutic challenge in diabetes and the critical care setting. *Diabet Med*. In press
  28. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. *Diabetologia* 2003;46(Suppl. 1):M9-M16
  29. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. *Diabetes Care* 2009;32(Suppl. 2):S232-S236
  30. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, Esposito K, Giugliano D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. *Circulation* 2005;111: 2518–2524
  31. Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, Cuddihy R. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. *Diabetes Technol Ther* 2008;10:149–159
  32. Tsujino D, Nishimura R, Taki K, Miyashita Y, Morimoto A, Tajima N. Daily glucose profiles in Japanese people with normal glucose tolerance as assessed by continuous glucose monitoring. *Diabetes Technol Ther* 2009;11:457–460